Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients

Journal of Clinical Investigation

Volumn 124, Issue 9, 2014, Pages 4082-4092

  Adair, Jennifer E ^a,b   Johnston, Sandra K ^b   Mrugala, Maciej M ^c   Beard, Brian C ^a,b   Guyman, Laura A ^d   Baldock, Anne L ^d   Bridge, Carly A ^d   Hawkins Daarud, Andrea ^d   Gori, Jennifer L ^a   Born, Donald E ^e   Gonzalez Cuyar, Luis F ^f   Silbergeld, Daniel L ^b,f   Rockne, Russell C ^d   Storer, Barry E ^a,c   Rockhill, Jason K ^b   Swanson, Kristin R ^d   Kiem, Hans Peter ^a,b,f  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DACARBAZINE; DNA METHYLTRANSFERASE; GUANINE; MGMT PROTEIN, HUMAN; O(6)-BENZYLGUANINE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONDITIONING; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; GENE THERAPY; GLIOBLASTOMA; HEMATOPOIETIC STEM CELL; HUMAN; MALE; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BONE MARROW; BRAIN NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY;

ADULT; BONE MARROW; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DACARBAZINE; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC THERAPY; GLIOBLASTOMA; GUANINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS;

EID: 84907010362     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76739     Document Type: Article

References (26)

1. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol. 2013;10(1): 14-26.
2. Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5): 459-466.
3. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoM.A. N Engl J Med. 2005;352(10): 987-996.
4. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications (Review). Clin Cancer Res. 2006;12(2): 328-331.
5. Quinn JA, et al. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioM.A. Neuro Oncol. 2009;11(5): 556-561.
6. Quinn JA, et al. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioM.A. J Clin Oncol. 2009;27(8): 1262-1267.
7. Allay JA, Dumenco LL, Koc ON, Liu L, Gerson SL. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood. 1995;85(11): 3342-3351.
8. Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE, Kiem H-P. Efficient and stable MGMTmediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest. 2010;120(7): 2345-2354.
9. Adair JE, et al. Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. Sci Transl Med. 2012;4(133): 133ra57.
10. Li J, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoM.A. Int J Radiat Oncol Biol Phys. 2011;81(3): 623-630.
11. Wen PY, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1072.
12. Neal ML, et al. Discriminating time to progression and survival using a response metric tuned to patient-specific glioblastoma kinetics. PLoS One. 2013;8(1): e51951.
13. Neal ML, et al. Resonse classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res. 2013;73(10): 2976-2986.
14. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191-205.
15. Yin AA, et al. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis. PLoS One. 2014;9(1): e85102.
16. Swanson KR, et al. Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle. Clin Oncol (R Coll Radiol). 2008;20(4): 301-308.
17. Swanson KR, Rostomily RC, Alvord EC J.R. A mathematical modelling tool for predicting survival of individual patients following resection of glioblastoma: a proof of principle. Br J Cancer. 2008;98(1): 113-119.
18. Wang CH, et al. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res. 2009;69(23): 9133-9140.
19. Swanson KR, Alvord EC Jr, Murray JD. Virtual brain tumours (gliomas) enhance the reality of medical imaging and hilight inadequacies of current therapy. Br J Cancer. 2002;86(1): 14-18.
20. Rockne R, et al. Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Phys Med Biol. 2010;55(12): 3271-3285.
21. Mandonnet E, et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003;53(4): 524-528.
22. Beard BC, Mezquita P, Morris JC, Kiem H-P. Efficient transduction and engraftment of G-CSF-mobilized peripheral blood CD34+ cells in nonhuman primates using GALVpseudotyped γ-retroviral vectors. Mol Ther. 2006;14(2): 212-217.
23. Swanson KR, Alvord EC Jr, Murray JD. A quantitative model for differential motility of gliomas in grey and white matter. Cell Prolif. 2000;33(5): 317-329.
24. Harpold HL, Alvord EC Jr, Swanson KR. The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol. 2007;66(1): 1-9.
25. Szeto MD, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69(10): 4502-4509.
26. Shaw EG, et al. Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GVM) patients [abstract]. Int J Radiat Oncol Biol Phys. 2003;57(2, Supplement).